Adam Tanious, M.D., MMSc, MBA

Adam Tanious, MD, MBA, MMSc is a faculty member of the MUSC Department of Surgery as an Associate Professor in the Division of Vascular Surgery. Since arriving to MUSC he has served as the associate program director of the vascular residency program and currently is the Medical Director of Vascular-Dialysis Access at MUSC Charleston. Dr. Tanious' clinical interests include the treatment of patients with aortic, carotid, peripheral arterial, and venous disease in addition to patients with End Stage Renal Disease. He likewise has a particular interest in multidisciplinary collaboration for complex cases where vascular mobilization and/or reconstruction is anticipated. His research interests revolve around innovation in surgery as well as surgical education.





Since Joining MUSC, Dr. Tanious has also earned his MBA and created/leads the Vascular Innovation Group efforts focused on developing new technologies in the field of vascular surgery.





He joined MUSC after completing his Vascular Surgery Integrated Residency + 2 years of dedicated research at Massachusetts General Hospital (MGH), where he served as Chief Resident in the Division of Vascular and Endovascular Surgery. Prior to his training at MGH, he completed a Master of Medical Science in Clinical and Translational Research, and his first 3 clinical years of Vascular Surgery Integrated Residency + 1 year of dedicated research at the University of South Florida. He earned his medical degree from Michigan State University.





He serves as a journal reviewer for the Journal of Vascular Surgery, Annals of Vascular Surgery and is a co-creator of the Vascular Education Video Library Consortium - a national, multi-institutional collaboration to create a centralized resource of subspecialty lectures and educational tools for vascular trainees.

He has over 50 peer-reviewed publications, 30 presentations, and multiple published abstracts and book chapters. He holds 1 patent and has submitted provisional patents for 2 other devices he hopes to bring to market to help the vascular patient population.